These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 9137453)

  • 1. Anti-estrogens potentiate the immunotherapy of the P815 murine mastocytoma by cytotoxic T lymphocytes.
    Nagy E; Baral E; Kangas L; Berczi I
    Anticancer Res; 1997; 17(2A):1083-8. PubMed ID: 9137453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination immunotherapy of the P815 murine mastocytoma with killer cells, IL-2 and anti-estrogens.
    Baral E; Nagy E; Kangas L; Berczi I
    Anticancer Res; 1997; 17(5A):3653-8. PubMed ID: 9413218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy of the H2712 murine mammary carcinoma with cytotoxic T lymphocytes and anti-estrogens.
    Baral E; Nagy E; Kangas L; Berczi I
    Anticancer Res; 1997; 17(5A):3647-51. PubMed ID: 9413217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy of the SL2-5 murine lymphoma with natural killer cells and tamoxifen or toremifene.
    Baral E; Nagy E; Kangas L; Berczi I
    Anticancer Res; 1997; 17(1A):77-83. PubMed ID: 9066633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-estrogens enhance the therapeutic effect of lymphokine-activated killer cells on the P815 murine mastocytoma.
    Baral E; Nagy E; Kangas L; Berczi I
    Int J Cancer; 1996 Aug; 67(4):580-5. PubMed ID: 8759619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effector cells of low-dose IL-2 immunotherapy in tumor bearing mice: tumor cell killing by CD8+ cytotoxic T lymphocytes and macrophages.
    Maas RA; Roest PA; Becker MJ; Weimar IS; Dullens HF; Den Otter W
    Immunobiology; 1992 Nov; 186(3-4):214-29. PubMed ID: 1490728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-specific suppressor T-cells which inhibit the in vitro generation of cytolytic T-cells from immune and early tumor-bearing host spleens.
    Bear HD
    Cancer Res; 1986 Apr; 46(4 Pt 1):1805-12. PubMed ID: 2936451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiestrogens sensitize human ovarian and lung carcinomas for lysis by autologous killer cells.
    Baral E; Nagy E; Krepart GV; Lotocki RJ; Unruh HW; Berczi I
    Anticancer Res; 2000; 20(3B):2027-31. PubMed ID: 10928146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The antimetastatic function of concomitant antitumor immunity. II. Evidence that the generation of Ly-1+2+ effector T cells temporarily causes the destruction of already disseminated tumor cells.
    Dye ES
    J Immunol; 1986 Feb; 136(4):1510-5. PubMed ID: 3080526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
    Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
    Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor cell surface expression of granulocyte-macrophage colony-stimulating factor elicits antitumor immunity and protects from tumor challenge in the P815 mouse mastocytoma tumor model.
    Soo Hoo W; Lundeen KA; Kohrumel JR; Pham NL; Brostoff SW; Bartholomew RM; Carlo DJ
    J Immunol; 1999 Jun; 162(12):7343-9. PubMed ID: 10358185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiestrogens affect both pathways of killer cell-mediated oncolysis.
    Haeryfar SM; Nagy E; Baral E; Krepart G; Lotocki R; Berczi I
    Anticancer Res; 2000; 20(3A):1849-53. PubMed ID: 10928117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progressive growth of immunogenic tumors: relationship between susceptibility of ascites P815 tumor cells to T-cell-mediated lysis and immune destruction in vivo.
    Fahey JR; Hines DL
    Cancer Res; 1987 Sep; 47(18):4759-65. PubMed ID: 3113723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific and nonspecific antitumor immunity. III. Specific T lymphocyte-mediated cytolysis of P815 mastocytoma and SL2 lymphoma by draining lymph node cells from syngeneic tumor-bearing DBA/2J mice.
    Germain RN; Williams RM; Benacerraf B
    Am J Pathol; 1976 Dec; 85(3):661-74. PubMed ID: 826167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenotype of syngeneic tumor-specific cytotoxic T-lymphocytes and requirements for their in vitro generation from tumor-bearing host and immune spleens.
    Bear HD; Susskind BM; Close KA; Barrett SK
    Cancer Res; 1988 Mar; 48(6):1422-7. PubMed ID: 2964266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes in vivo.
    Ley V; Langlade-Demoyen P; Kourilsky P; Larsson-Sciard EL
    Eur J Immunol; 1991 Mar; 21(3):851-4. PubMed ID: 2009918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infiltration and accumulation of precursor cytotoxic T-cells increase with time in progressively growing ocular tumors.
    Ksander BR; Bando Y; Acevedo J; Streilein JW
    Cancer Res; 1991 Jun; 51(12):3153-8. PubMed ID: 1904003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of suppressor cells in mice bearing syngeneic mastocytoma.
    Takei F; Levy JG; Kilburn DG
    J Immunol; 1977 Feb; 118(2):412-7. PubMed ID: 65423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of cytotoxic T cell responses to intracameral allogeneic tumors.
    Ksander BR; Streilein JW
    Invest Ophthalmol Vis Sci; 1989 Feb; 30(2):323-9. PubMed ID: 2492486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent effector function of tumor-sensitized L-selectin(low) T cells against subcutaneous tumors requires LFA-1 co-stimulation.
    Seeley BM; Barthel SW; To WC; Kjaergaard J; Shu S; Plautz GE
    Otolaryngol Head Neck Surg; 2001 Apr; 124(4):436-41. PubMed ID: 11283503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.